Clinical Trial Update: The Safety and Efficacy of Eculizumab in Japanese Patients With Atypical Hemolytic Uremic Syndrome (aHUS) [Phase 2]

View source ↗

Summary

Phase 2 trial assessing the safety and efficacy of eculizumab in Japanese patients with atypical hemolytic uremic syndrome (aHUS) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atypical Hemolytic Uremic Syndrome

Drugs mentioned

• SOLIRIS (eculizumab)

Snippet

Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: Atypical Hemolytic Uremic Syndrome (aHUS) | Phase 2 | Status: COMPLETED